Notice2024-18381
Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 16, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Center for Advancing Translational Sciences (NCATS), both institutes of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Autala Bio Inc., A Civala Company ("Autala"), incorporated in Delaware.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 159 (Friday, August 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 159 (Friday, August 16, 2024)]
[Notices]
[Pages 66730-66731]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-18381]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Dimethyl
Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory
Diseases
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Alcohol Abuse and Alcoholism (NIAAA)
and the National Center for Advancing Translational Sciences (NCATS),
both institutes of the National Institutes of Health (NIH), Department
of Health and Human Services (HHS), are contemplating the grant of an
Exclusive Patent License to practice the inventions embodied in the
Patents and Patent Applications listed in the Supplementary Information
section of this notice to Autala Bio Inc., A Civala Company
(``Autala''), incorporated in Delaware.
DATES: Only written comments and/or applications for a license that are
received by the National Heart Lung and Blood Institute (NHLBI) Office
of Technology Transfer And Development (OTTAD) on or before September
3, 2024 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Jillian Varonin, Ph.D., Technology Transfer
Manager, NHLBI Office of Technology Transfer And Development,
Telephone: (301) 496-0505; Email: <a href="/cdn-cgi/l/email-protection#deb4b7b2b2b7bfb0f0a8bfacb1b0b7b09eb0b7b6f0b9b1a8"><span class="__cf_email__" data-cfemail="8ce6e5e0e0e5ede2a2faedfee3e2e5e2cce2e5e4a2ebe3fa">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 61/624,741,
filed April 16, 2012, entitled ``Derivatives Of Docosahexaenoylamide
and Uses Thereof'' [HHS Reference No. E-070-2012-0-US-01];
2. PCT Patent Application No. PCT/US2013/032333, filed March 15,
2013, entitled ``Derivatives Of Docosahexaenoylamide and Uses Thereof''
[HHS Reference No. E-070-2012-0-PCT-02];
3. European Patent No. 2847178, filed March 15, 2013, entitled
``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS Reference
No. E-070-2012-0-EP-03];
4. United States Patent No. 9,422,308, filed September 23, 2014,
entitled ``Derivatives Of Docosahexaenoylamide
[[Page 66731]]
and Uses Thereof'' [HHS Reference No. E-070-2012-0-US-04];
5. Germany Patent No. 602013016154.2, filed October 30, 2014,
entitled ``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS
Reference No. E-070-2012-0-DE-05];
6. France Patent No. 2847178, filed October 30, 2014, entitled
``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS Reference
No. E-070-2012-0-FR-06];
7. Great Britain Patent No. 2847178, filed October 30, 2014,
entitled ``Derivatives Of Docosahexaenoylamide and Uses Thereof'' [HHS
Reference No. E-070-2012-0-GB-07].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Use of a G-protein-coupled receptor 110 (``GPR110'') agonist
named dimethyl synaptamide (``DMS'') (also known as Compound
NCGC00248435; (4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-hydroxy-2-methylpropyl)
docosa-4,7,10,13,16,19-hexaenamide; or ``A8'') to treat multiple
sclerosis (``MS''), chronic inflammatory demyelinating
polyradiculoneuropathy (``CIDP''), psoriasis, inflammatory bowel
disease (``IBD''), Crohn's disease, ulcerative colitis (``UC''),
sclerosing cholangitis, ankylosing spondylitis, rheumatoid arthritis
(``RA''), psoriatic arthritis, systemic lupus erythematosus (``SLE''),
lupus nephritis, sarcoidosis, and Behcet's disease.''
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the NHLBI
Office of Technology Transfer And Development receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National
Heart, Lung, and Blood Institute.
[FR Doc. 2024-18381 Filed 8-15-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 16, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.